Application of molecular biology of differentiated thyroid cancer for clinical prognostication

  1. Antongiulio Faggiano3
  1. 1IOS & COLEMAN Srl, Naples, Italy
  2. 2Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
  3. 3Thyroid and Parathyroid Surgery Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori-IRCCS “Fondazione G. Pascale”, Naples, Italy
  1. Correspondence should be addressed to V Marotta; Email: vinc.endo{at}
  1. Figure 1

    Clinical outcome of differentiated thyroid cancer in 2 large cohorts. Data from Tuttle et al. (2010b), and Pitoia et al. (2013) (A and B, respectively).

  2. Figure 2

    Current status of molecular characterisation of differentiated thyroid cancer.

  3. Figure 3

    Association between BRAFV600E and tumour-related mortality (A) and recurrence (B) in 2 large multicentre cohorts. Data from Xing et al. (2013) and Xing et al. (2015), respectively. *Significantly different at univariate analysis; **Significantly different at multivariate analysis.

  4. Figure 4

    Synergistic prognostic effect of co-occurrence of BRAF V600E and TERT promoter mutations in increasing the risk of tumour recurrence (ATYPESETTER: Please change “8,7%, 16,3%, 19,2%, 68,6%” to “8.7%, 16.3%, 19.2%, 68.6%” in the Figure 4. and B) and disease-related mortality (C and D) in DTC. Data from Xing et al. (2014b) (A), Xing et al. (2014a) (C), and Song et al. (2016) (B and D). †Not significantly different from the No mutations group; *Significantly different from the No mutations group; **Significantly different from the TERT promoter mutations only group; *** Significantly different from the BRAF V600E only group.

| Table of Contents